| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | myriocin | CTRPv2 | pan-cancer | AAC | 0.01 | 0.9 |
| mRNA | avicin D | CTRPv2 | pan-cancer | AAC | 0.0068 | 0.9 |
| mRNA | TW 37 | GDSC1000 | pan-cancer | AAC | 0.0041 | 0.9 |
| mRNA | temsirolimus | GDSC1000 | pan-cancer | AAC | 0.0042 | 0.9 |
| mRNA | BYL-719 | CTRPv2 | pan-cancer | AAC | -0.0052 | 0.9 |
| mRNA | dabrafenib | CTRPv2 | pan-cancer | AAC | -0.0057 | 0.9 |
| mRNA | selumetinib:MK-2206 (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0043 | 0.9 |
| mRNA | WZ-1-84 | GDSC1000 | pan-cancer | AAC | -0.0062 | 0.9 |
| mRNA | BRD-K02251932 | CTRPv2 | pan-cancer | AAC | 0.0045 | 0.9 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | -0.0038 | 0.9 |